
Aspercreme
TINA.org investigates after doctor challenges pain reliever’s “clinically proven” labeling claim on Twitter.
Case Name (Date) |
Cruz et al v. Sanofi US Corp. 21-cv-5536, N.D. Cal. (May 2021) |
---|---|
Product/Service | Aspercreme Pain Relief Patch |
Allegations | Making misleading pain relief claims
Misleadingly marketing the product as “Max Strength” when other products deliver more lidocaine and are more effective Misleadingly marketing the patch as “fast acting” when it does not provide immediate pain relief Falsely claim that the product provides 12 hours of relief when the patch does not stay on for even six hours Falsely marketing the product as compliant with FDA regulations when it is not |
Status | Pending |
TINA.org investigates after doctor challenges pain reliever’s “clinically proven” labeling claim on Twitter.
NAD tells marketer to watch its mouth when it comes to making certain dry mouth product claims.